Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
|Videos|July 3, 2017
Is One Immunotherapy for Lung Cancer Better Than the Rest?
Author(s)Melissa L. Johnson, MD
This video reviews immunotherapy options now available for the treatment of lung cancer across different lines of therapy.
Advertisement
In this video, Melissa L. Johnson, MD, of Sarah Cannon Research Institute in Nashville, Tennessee, reviews immunotherapy options now available for the treatment of lung cancer across different lines of therapy and highlights upcoming research in this setting.
Johnson gave a presentation on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting last month in Chicago.
Advertisement
Related to this article
Medical oncologists, clinical pharmacists, and oncologic nurse practitioners share the presentation topics to look out for at WCLC 2026.
The interim 3-year OS rates were 71.2% with OST-HER2 vs 45.8% in historical controls in a phase 2b trial of fully resected, pulmonary metastatic osteosarcoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
3
What Were the Key Hematologic Oncology Takeaways from SOHO 2026?
4
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
5